Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Vertex Pharmaceuticals' Chief Commercial Officer, Duncan McKechnie, sold 2,633 shares of common stock for approximately $1.3 million under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Chief Commercial Officer, Duncan McKechnie, sold 2,437 shares of common stock for $475.3 per share under a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' EVP and Chief Legal Officer, Joy Liu, sold 892 shares of common stock for $495.96 per share under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 2,329 shares of common stock for $480.31 per share under a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' SVP & Chief Accounting Officer, Kristen Ambrose, sold 357 shares of common stock for $483.36 per share under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Chief Operating Officer, and Chief Financial Officer, Charles F. Wagner Jr., disposed of 1,744 shares of common stock to cover tax withholding obligations.

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold 260 shares of common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP Amit Sachdev sold VRTX common stock totaling 3,364 shares, including tax-related dispositions, under a pre-arranged trading plan.

Vertex Pharmaceuticals' Chief Commercial Officer, Duncan McKechnie, sold 5,783 shares of common stock in pre-scheduled transactions.

Vertex Pharmaceuticals' Executive Chairman, Jeffrey M. Leiden, reported the disposition of 3,547 common shares at $485.11 for tax purposes.

Vertex Pharmaceuticals CEO Reshma Kewalramani disposed of 4,981 common shares at $485.11 each to cover tax liabilities, as part of a pre-arranged plan.

Vertex Pharmaceuticals' EVP and Chief Scientific Officer, Mark E. Bunnage, reported the sale of company common stock, including shares withheld for tax obligations.

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, disposed of 1,453 shares of common stock at $485.11 per share under a pre-arranged 10b5-1 plan.

Vertex Pharmaceuticals' EVP and Chief Legal Officer, Jonathan Biller, disposed of common stock through tax withholding and a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Chief Technical Operations Officer, Edward Morrow Atkinson III, sold shares of common stock totaling 668 shares under a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' SVP & Chief Accounting Officer, Kristen Ambrose, reported the sale of company common stock, including shares for tax withholding.

Vertex Pharmaceuticals EVP Amit Sachdev exercised stock options and subsequently sold a significant number of shares under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP and CFO, Charles F. Wagner Jr., reported the acquisition of restricted stock units and the disposition of shares for tax purposes.

Vertex Pharmaceuticals EVP Ourania Tatsis acquired restricted stock units and sold common stock shares under a Rule 10b5-1 plan.

Vertex Pharmaceuticals EVP Amit Sachdev reported the acquisition of 5,789 restricted stock units and the disposition of 2,140 common shares.

Vertex Pharmaceuticals' EVP, Chief Commercial Officer, Duncan McKechnie, received a restricted stock unit award and subsequently disposed of shares, adjusting his beneficial ownership.

Vertex Pharmaceuticals' Executive Chairman, Jeffrey M. Leiden, filed a Form 4 detailing future acquisition of 8,269 restricted stock units and subsequent disposition of 2,964 shares for tax purposes.

Vertex Pharmaceuticals CEO Reshma Kewalramani reported the acquisition of restricted stock units and the disposition of shares for tax withholding purposes.

Vertex Pharmaceuticals' Chief Scientific Officer, Mark E. Bunnage, reported the acquisition of restricted stock units and subsequent sales of common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP and Chief Medical Officer, Carmen Bozic, reported an acquisition of restricted stock units and a related disposition for tax purposes.

Vertex Pharmaceuticals' EVP and Chief Legal Officer, Jonathan Biller, reported acquiring restricted stock units and selling common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Chief Technical Operations Officer Edward Morrow Atkinson III, reported an acquisition of restricted stock units and subsequent sales of common stock under a Rule 10b5-1 plan.

Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals, acquired restricted stock units and subsequently sold shares under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Chief Operating Officer, and Chief Financial Officer, Charles F. Wagner Jr., disposed of 3,045 shares of common stock to cover tax withholding obligations.

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold shares totaling $215,000 under a pre-arranged 10b5-1 trading plan.